Travere Therapeutics Inc (NAS:TVTX)
$ 6.34 -0.22 (-3.35%) Market Cap: 481.14 Mil Enterprise Value: 463.52 Mil PE Ratio: 0 PB Ratio: 6.52 GF Score: 58/100

Q4 2018 Retrophin Inc Earnings Call Transcript

Feb 26, 2019 / 09:30PM GMT
Release Date Price: $21.34 (-0.14%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Retrophin Inc. Fourth Quarter and Full Year 2018 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Chris Cline. Sir, you may begin.

Chris Cline
Retrophin, Inc. - VP of IR & Corporate Communications

Great. Thank you, Tom. Good afternoon, everyone, and welcome to Retrophin's Fourth Quarter and Full Year 2018 Financial Results and Corporate Update Call. Today's call will be led by Eric Dube, our Chief Executive Officer. Eric will be joined by our Chief Medical Officer, Dr. Noah Rosenberg; and our Chief Financial Officer, Laura Clague for their prepared remarks. Neil McFarlane, our Chief Operating Officer; and Dr. Bill Rote, our Senior Vice President of Research and Development will be joining us for the Q&A session.

Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot